The primary symptoms of chronic inflammatory demyelinating polyneuropathy include impaired motor function, loss of sensation and a symmetric weakness in the arms and legs that lasts longer than eight weeks, according to the National Organization for Rare Disorders. Other symptoms include lethargy, pain, double vision, abnormal walking and difficulty swallowing. These symptoms come and go for some affected individuals, while they are present throughout for others.
CIDP is a rare disorder that affects the body's nervous system, explains NORD. It causes inflammation in both the peripheral nerves and the nerve roots and destroys the myelin sheaths covering the nerves. While the cause is unknown as of 2015, CIDP strongly presents as an autoimmune disorder, as the body's immune system seems to attack healthy tissue instead of infections. CIDP affects everyone across all age groups, though its onset is usually around the age of 50. Men are twice as likely as women to get the disorder.
Routine treatments for CIDP include glucocorticoids with and without immunosuppressive drugs, intravenous immunoglobulin and plasma exchange, states NORD. As of 2015, clinical trials are being conducted that involve monoclonal antibodies, such as rituximab and alemtuzumab, and drugs like fingolimod, which affects the lymphocytes of the immune system.